Significantly Decreased LMK‑CT Score vs Placebo at Week 24 (Key Secondary Endpoint) With Sustained Improvement Through Week 52 (Other Secondary Endpoint) in SINUS‑521,2,a
aAnalysis of change at Week 52 was not multiplicity controlled; result is descriptive.
SEE THE SCANS FROM A REAL DUPIXENT PATIENT
Click and drag
to see results
to see results
CT scan of patient from clinical trial. Individual results may vary.
SINUS-52
CHANGE IN LMK-CT SCORES1,2,a
aAnalysis of change at Week 52 was not multiplicity controlled; result is descriptive.
DUPIXENT
demonstrated statistically significant reductions in opacification across all individual sinuses AT
WEEK 241,2
Lund-Mackay computed tomography (LMK-CT) score (range 0 to 24): reduced score indicates improvement.
Explore the Safety Data and Study Designs
Dosage and
Administration
Administration
See the recommended dosing and administration options for patients on DUPIXENT.